---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-105818"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:30:40.913422+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Novavax completes U.S. marketing authorization transfer to Sanofi for Nuvaxovid, earns $25M milestone

## Summary
- FDA approved transfer of U.S. marketing authorization for Nuvaxovid from Novavax to Sanofi on Nov 3, 2025.
- Second $25M milestone payment triggered; follows EU transfer in Oct 2025. Payment expected Q1 2026.
- Total non-dilutive capital secured YTD 2025 from Sanofi milestones is $225M.
- Sanofi now responsible for U.S. commercial and regulatory activities for Nuvaxovid.
- CEO John C. Jacobs notes delivery on partnership obligations and future royalties.

## SEC filing metadata
- accession: 0001104659-25-105818
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000110465925105818/0001104659-25-105818-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000110465925105818/tm2530132d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-105818
- JSON: https://secwatch.observer/filing/0001104659-25-105818.json
- Plain text: https://secwatch.observer/filing/0001104659-25-105818.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.